Lipocine is trading 23.4% up at $2.59 before the October 7, 2026 open, with the catalyst unclear. - The October 6 close was $2.10. - The latest notable company news was the September 14 initiation of a Phase 3 study for postpartum depression; it predates this move and does not establish its cause. - Broad market futures are mildly lower, which does not explain the increase.